Drug-induced vasculitides

Dubost, Jean‐Jacques; Souteyrand, P; Sauvezie, B

doi:10.1016/s0950-3579(05)80299-7

Cited by 38 publications

(12 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other investigations confirmed normal renal function, cryoglobulins were not detected. IgG was 13.5 g/l (7)(8)(9)(10)(11)(12)(13)(14), IgA 4.39 g/l (0.8-4.0), IgM 0.82 g/l (0.45-2.0), and pANCA 1/80; anti-MPO was not detected. CT scan of the chest showed diffuse multilobular bronchiectatic changes in both lung fields.…”

Section: Case Reportmentioning

confidence: 98%

Chronic suppurative lung disease with associated vasculitis

Bruce

McAteer

Gardiner

et al. 1995

Postgraduate Medical Journal

View full text Add to dashboard Cite

show abstract

Section: Case Reportmentioning

confidence: 98%

Chronic suppurative lung disease with associated vasculitis

Bruce

McAteer

Gardiner

et al. 1995

Postgraduate Medical Journal

View full text Add to dashboard Cite

show abstract

“…They can be primary, or secondary to other autoimmune conditions, drugs or infections 1 2 3. Depending on the size of the blood vessels involved and the organ distribution of the vasculitis, the primary systemic vasculitides are classified into discrete clinical syndromes 4.…”

mentioning

confidence: 99%

Modification and validation of the Birmingham Vasculitis Activity Score (version 3)

Mukhtyar

Lee

Brown

et al. 2008

Annals of the Rheumatic Diseases

939

611

View full text Add to dashboard Cite

Background:Comprehensive multisystem clinical assessment using the Birmingham Vasculitis Activity score (BVAS) is widely used in therapeutic studies of systemic vasculitis. Extensive use suggested a need to revise the instrument. The previous version of BVAS has been revised, according to usage and reviewed by an expert committee.Objective:To modify and validate version 3 of the BVAS in patients with systemic vasculitis.Methods:The new version of BVAS was tested in a prospective cross-sectional study of patients with vasculitis.Results:The number of items was reduced from 66 to 56. The subscores for new/worse disease and persistent disease were unified. In 313 patients with systemic vasculitis, BVAS(v.3) correlated with treatment decision (Spearman’s rs = 0.66, 95% CI 0.59 to 0.72), BVAS1 of version 2 (rs = 0.94, 95% CI 0.92 to 0.96), BVAS2 of version 2 in patients with persistent disease (rs = 0.60, 95% CI 0.21 to 0.83), C-reactive protein levels (rs = 0.43, 95% CI 0.31 to 0.54), physician’s global assessment (rs = 0.91, 95% CI 0.89 to 0.93) and vasculitis activity index (rs = 0.88, 95% CI 0.86 to 0.91). The intraclass correlation coefficients for reproducibility and repeatability were 0.96 (95% CI 0.95 to 0.97) and 0.96 (95% CI 0.92 to 0.97), respectively. In 39 patients assessed at diagnosis and again at 3 months, the BVAS(v.3) fell by 17 (95% CI 15 to 19) units (p<0.001, paired t test).Conclusion:BVAS(v.3) demonstrates convergence with BVAS(v.2), treatment decision, physician global assessment of disease activity, vasculitis activity index and C-reactive protein. It is repeatable, reproducible and sensitive to change. The new version of BVAS is validated for assessment of systemic vasculitis.

show abstract

“…Drugs such as penicillin, sulphonamides, anticonvulsants, and thiazides have also been implicated. 3 7…”

mentioning

confidence: 99%

“…37 A morelikely explanation is that zafirlukast improved the patients' asthma significantly enough to withdraw oral corticosteroids, unmasking an underlying vasculitis 3. The appearance of Churg-Strauss syndrome has certainly been documented in corticosteroid dependent asthma patients in whom the prednisolone dose was decreased or discontinued—two of these cases were fatal 5.…”

mentioning

confidence: 99%